<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To study efficacy and safety of cholinergic therapy in patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> or combined Alzheimer's and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> and marked somatic pathology, 30 patients, aged from 54-85 years, with mild or moderate <z:hpo ids='HP_0000726'>dementia</z:hpo> have been studied </plain></SENT>
<SENT sid="1" pm="."><plain>Patients were treated with rivastigmine (exelon) in dosage 3-12 mg daily during 3 months </plain></SENT>
<SENT sid="2" pm="."><plain>The safety of the drug for patients with comorbid somatic pathology has been shown: during the treatment no severe aversive effects or strengthening of diseases of visceral organs were observed </plain></SENT>
<SENT sid="3" pm="."><plain>The improvement of global clinical state as well as reduction of cognitive and <z:hpo ids='HP_0000708'>behavioral disorders</z:hpo> indicate the high effectiveness of exelon </plain></SENT>
<SENT sid="4" pm="."><plain>The recommendations allowing to improve the tolerability of treatment with exelon of patients with comorbid pathology of visceral organs are worked out </plain></SENT>
</text></document>